Biotech Values

[DewDiligence]

(RVNC)—4Q18 worldwide Botox sales=$945.9M, +12% YoY (+7.5% QoQ*):

http://phx.corporate-ir.net/External.File?t=1&item=VHlwZT0yfFBhcmVudElEPTUyNzcwMDh8Q2hpbGRJRD03MDM1MTE=

• US therapeutic: $433.3M (+13 YoY)
• US cosmetic: $258.1.0M (+13% YoY)
• Ex-US therapeutic: $96.7 (+7 YoY in constant currency)
• Ex-US cosmetic: $157.8M (+9% YoY in constant currency)

All told, 73% of Botox sales were in the US, where the therapeutic/cosmetic split was 63/37; 27% of Botox sales were ex-US, where the therapeutic/cosmetic split was 38/62.

*The large 4Q18 increase relative to 3Q18 was expected; Botox is seasonally stronger in the second and fourth quarters of the calendar year.